IP Library Granted Patent US 8,071,661
Granted Patent B2
US 8,071,661 · App. 12/329,700 · Granted Dec 6, 2011

Biomedical devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,661
App. No.
12/329,700
Granted
Dec 6, 2011
Kind
B2
Abstract

Biomedical devices are provided herein which are formed from a polymerization product of a mixture comprising (a) a copolymer which is the reaction product of one or more polymerizable polyhydric alcohols and one or more polymerizable fluorine-containing monomers; and (b) a biomedical device-forming comonomer.

Claims (20)

1. A biomedical device obtained from a polymerization product of a mixture comprising (a) a copolymer which is the reaction product of one or more polymerizable polyhydric alcohols and one or more polymerizable fluorine-containing monomers; and (b) a biomedical device-forming comonomer.

2. The biomedical device of claim 1 , wherein the polymerizable polyhydric alcohol is a polyhydric alcohol terminated with a polymerizable ethylenically unsaturated radical and the polymerizable fluorine-containing monomer is a fluorine-containing monomer terminated with a polymerizable ethylenically unsaturated radical.

3. The biomedical device of claim 1 , wherein the polymerizable polyhydric alcohol is selected from the group consisting of polymerizable glycerol, polymerizable erythritol, polymerizable xylitol, polymerizable sorbitol and mixtures thereof.

4. The biomedical device of claim 1 , wherein the polymerizable polyhydric alcohol is selected from the group consisting of glycerol (meth)acrylate, erythritol (meth)acrylate, xylitol (meth)acrylate, sorbitol (meth)acrylate and mixtures thereof.

5. The biomedical device of claim 1 , wherein the polymerizable fluorine-containing monomer is a fluorinated (meth)acrylate monomer.

6. The biomedical device of claim 1 , wherein the polymerizable fluorine-containing monomer is selected from the group consisting of 2,2,2-trifluoroethyl (meth)acrylate, 2,2,3,3-tetrafluoropropyl (meth)acrylate, 2,2,3,3,3,-pentafluoropropyl (meth)acrylate, 1-trifluoromethyl-2,2,2-trifluoroethyl (meth)acrylate, 1H,1H,5H-octafluoropentyl (meth)acrylate, hexafluoroisopropyl (meth)acrylate, 2,2,3,3,4,4-hexafluorobutyl (meth)acrylate and mixtures thereof.

7. The biomedical device of claim 1 , wherein the copolymer is terminated with an ethylenically unsaturated-containing radical.

8. The biomedical device of claim 1 , wherein the biomedical device-forming comonomer is a silicone-containing monomer.

9. The biomedical device of claim 1 , wherein the mixture further comprises a hydrophilic monomer, hydrophobic monomer or both.

10. The biomedical device of claim 9 , wherein the hydrophilic monomer is selected from the group consisting of 2-hydroxyethylmethacrylate, 2-hydroxyethylacrylate, glyceryl methacrylate, N-vinyl pyrrolidone, N-vinyl-N-methyl acetamide, N, N-dimethyl methacrylamide, N,N-dimethylacrylamide, acrylic acid, methacrylic acid and mixtures thereof.

11. The biomedical device of claim 9 , wherein the hydrophobic monomer is a silicone-containing monomer having from 1 to about 20 silicon atoms.

12. The biomedical device of claim 11 , wherein the silicone monomer is 3-methacryloxypropyl tris(trimethylsiloxy)silane.

13. The biomedical device of claim 9 , wherein the hydrophobic monomer is an aliphatic ring containing monomer selected from the group consisting of isobornyl acrylate, isobornyl methacrylate, cyclohexyl acrylate, cyclohexyl methacrylate and mixtures thereof.

14. The biomedical device of claim 1 , wherein component (a) comprises about 0.1 to about 50 weight percent of the mixture and the biomedical device-forming comonomer component (b) comprises about 50 to about 99.9 weight percent of the mixture.

15. The biomedical device of claim 1 , wherein component (a) comprises about 0.25 to about 30 weight percent of the mixture and the biomedical device-forming comonomer component (b) comprises about 70 to about 99.75 weight percent of the mixture.

16. The biomedical device of claim 1 , wherein component (a) comprises about 1 to about 10 weight percent of the mixture and the biomedical device-forming comonomer component (b) comprises about 90 to about 99 weight percent of the mixture.

17. The biomedical device of claim 1 , which is an ophthalmic lens.

18. The biomedical device of claim 17 , wherein the ophthalmic lens is a contact lens.

19. The biomedical device of claim 18 , wherein the contact lens is a rigid gas permeable lens.

20. The biomedical device of claim 1 , which is a hydrogel.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Apr 23, 2012
From: BAUSCH & LOMB INCORPORATED
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
Reel/Frame 028090/0019 →